key: cord-1048529-m493ns7f
authors: Aytha, Swathi P; Regan, A; Grinshteyn, E; Nosek, M; Gu, NY
title: P61 COVID-19 Concerns Experienced by Pregnant and Postpartum Women and Their Influence on Health-Related Quality-of-Life
date: 2022-01-31
journal: Value in Health
DOI: 10.1016/j.jval.2021.11.059
sha: 59bc6327c2ad96686deb2f5735bf77a5c6ccb22f
doc_id: 1048529
cord_uid: m493ns7f

nan

Objectives: The EQ-5D is a widely used instrument to measure patient-reported outcomes and health state utility values. This study aimed to report normative data for the EQ-5D-5L questionnaire in Italy based on a nationally representative sample. Methods: This study is part of the EQ-5D-5L Italian valuation study. The target participants were a sample of the Italian adult population (aged 18 and above) and were recruited through a market research company. Eleven trained interviewers conducted one-to-one interviews using a videoconferencing software (Zoom) and a survey web application (LimeSurvey) between November 2020 and February 2021. The distribution of answers was estimated for the descriptive system of the EQ-5D-5L, and descriptive statistics were calculated for the visual analogue scale (EQ-VAS). Data analysis was performed using Stata (StataCorp). Results: The sample was composed of 1,182 people and fully represented the Italian population (2020) in terms of age, gender, and geographical area. Mean age was 48.3; men were 48.7%. Half of the participants selected the two most common health states (i.e., '11111' and '11112') . Mean VAS was 81.8, and steadily decreased with increasing age (from 87.0 in the 18-24 group to 75.1 among the over 75). In participants affected by chronic illness (39%), mean VAS dropped to 75.5. At least one problem (from slight to extreme) was reported by 12.1% of respondents for mobility, 4.2% for selfcare, 11.6% for usual activity, 43.3% for pain/discomfort and 41.2% for anxiety/depression. The frequency of problems generally increased with age, except for the last dimension, where 56% among the youngest reported complaints versus 30% of participants aged 75 and above. Moreover, self-reported anxiety/depression was far more common in women (49.7%) than in men (32.3%). Conclusions: EQ-5D-5L population norms provide useful insights into the health status of the Italian population and can be used as reference values for future surveys using the same tool.

TO WHAT EXTENT IS EQ-5D USED AS A TOOL FOR CLINICAL OUTCOME ASSESSMENT? Shaw C, 1 Longworth L, 1 Bennett B, 2 Ruane P, 3 Watson C, 1 Francis LE, 1 Shaw J 4 1 PHMR Ltd., London, UK, 2 Bristol-Myers Squibb, Uxbridge, UK, 3 PHMR Ltd., Newcastle upon Tyne, NBL, UK, 4 Bristol-Myers Squibb, Lawrenceville, NJ, USA Objectives: The EQ-5D is widely used to inform economic evaluations of health technologies. However, the extent of its use for clinical outcome assessment (COA) is unclear. This review identified the prevalence with which EQ-5D data are evaluated by health authorities in clinical benefit assessments. Methods: Drug technology assessments (TAs) published by HTA agencies in England, France, Germany and the US during the last 2 years were identified. Product labelling for drugs approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) over the last 5 years were also reviewed. Only documents reporting EQ-5D as a COA measure were included. Results: EQ-5D data were reported for COA in 139 TAs with the majority reported for Germany (n=78) and the remainder for England (n=46), France (n=12) and the US (n=3). Visual analogue scale (VAS) scores were presented most frequently (n=111) followed by utility index scores (n=48) and dimension levels (n=1). The VAS accounted for 99% of EQ-5D reports in Germany. Minimally important differences (MIDs) were discussed in 51 TAs: 34% and 24% of VAS and index score reports, respectively. Three-hundred twenty drugs were approved by the EMA and 735 by the FDA, and among these 15 and 35, respectively, presented EQ-5D data for COA. All EQ-5D data submitted to the FDA were reported in supporting documentation. Index scores, VAS scores and dimension levels were cited for 32, 26 and 5 drugs, respectively. Discussion of MIDs was more frequent in EMA documents (35%) than FDA documents (11%). Conclusions: The EQ-5D has been used for COA in HTA submissions; most frequently the VAS in German TAs. EQ-5D was also used to support labelling claims in a minority of EMA and FDA decisions. No EQ-5D data were reported in FDA product labelling, which suggests that the data were not considered material.

A NEW ONLINE TOOL FOR VALUING HEALTH STATES: ELICITING PERSONAL UTILITY FUNCTIONS FOR THE EQ-5D-5L Schneider P, 1 van Hout B, 2 Heisen M, 3 Brazier JE, 2 Devlin N 4 1 University of Sheffield, Sheffield, NW, UK, 2 University of Sheffield, Sheffield, UK, 3 Pharmerit International, Rotterdam, Netherlands, 4 University of Melbourne, Melbourne, VIC, Australia Objectives: Standard health valuation methods, such as TTO or DCE are inefficient. They require data from hundreds if not thousands of participants to generate utility values (=value sets) for health descriptive systems. Here, we present the Online elicitation of Personal Utility Functions (OPUF) tool; a new type of online survey for valuing EQ-5D-5L health states using more efficient, compositional preference elicitation methods, which allows estimating value sets on the individual level. The Objectives: of this study are to report on the development of the tool, and to test the feasibility of using it to obtain individual-level value sets for the EQ-5D-5L. Methods: We used an iterative design approach to adapt the PUF method, previously proposed by Devlin et al., for the EQ-5D-5L and for use as a standalone online tool. The valuation consists of three steps: level rating, dimension weighting, and anchoring. We conducted three iterative rounds of qualitative interviews to get feedback on the tasks and then piloted the tool in a sample of 50 participants from the UK. Results: On average, it took participants about 10 minutes to go through all tasks. Their responses indicated a good level of engagement. The two most important EQ-5D dimensions were Pain/Discomfort and Mobility. For 46 (92%) participants, we were able to construct a personal utility function. The results revealed that health state preferences differ considerably between individuals. Conclusions: We successfully piloted the OPUF tool and showed that it can be used to derive a social as well as personal utility functions for the EQ-5D-5L. Even though the development of the online tool is in an early stage, there are potential avenues for further research. With some further abstraction, the OPUF tool could provide a modular software platform for creating valuation tools for any health descriptive system.

Objectives: Pregnant and postpartum women may be particularly susceptible to pandemic-induced anxiety/depression, which can adversely affect maternal and infant health. This study investigates the COVID-19 concerns experienced by pregnant and postpartum women and their Influence on health-related quality-of-life (HRQoL). Methods: We conducted an online, national US survey (EuroQol grant: 260-2020RA) between May and June 2021. Respondents completed the EQ-5D-5L instrument and rated their level of concerns for their own health, their baby's health, and their family's health, being pregnant and giving birth during the pandemic. Women indicated whether they strongly agreed, agreed, neither agreed nor disagreed, disagreed or strongly disagreed with each concern. Respondents who indicated they "strongly agreed" were classified as having strong concerns. We used median regression to estimate the EQ-5D-5L utility and EQ-VAS scores by level of maternal concerns. Results: Among 2,070 respondents, pregnant and postpartum women commonly expressed strong concerns about giving birth during the pandemic (44%; 95% CI 39%, 48%), the health of their baby (44%; 95% CI 40%, 48%), the health of their family (38%; 95% CI 34%, 42%), and being pregnant during the pandemic (38%; 95% CI 34%, 42%). Fewer respondents expressed strong concerns about their own health (27%; 95% CI 23%, 31%). Overall, there was no association between HRQoL measures and maternal concerns during COVID-19. Among women who gave birth during 2020 (n=536), each unit increase in concerns about being pregnant was associated a 0.02 decline in the EQ-5D-5L utility (95% CI -0.04, -0.01). No difference was observed in EQ5D-VAS scores (ß=0.00; 95% CI -0.01, 0.01). No other differences in HRQoL were observed. Conclusions: Although overall, there was no relationship between maternal concerns during the COVID-19 pandemic and HRQoL, we did observe small declines in HRQoL associated with concern of being pregnant during the pandemic among women pregnant early in the pandemic.

Heinrich M, 1 Mulgina D, 1 Kudlac A, 1 Ouyang C, 1 Larkin M, 2 Ofori A 3 1 Vitaccess, Oxford, LON, UK, 2 Vitaccess, London, LON, UK, 3 Vitaccess, London, OXF, UK Objectives: The Melanoma UK digital registry, launched in collaboration with Melanoma UK in 2017, captures real-world patient-reported quality of life (QoL), symptoms, and side effects of melanoma treatment using a mobile application. 729 UK patients with melanoma have since joined the registry, with approximately 60% of participants in Stage 3 and 4 of the disease. Due to the COVID-19 pandemic, a national lockdown was announced in the UK in March 2020 with an instruction to stay at home, particularly for vulnerable people with health conditions. The impact of the fundamental changes in day-to-day living and the delivery of healthcare on people diagnosed with melanoma needs to be better understood. This study explored if the COVID-19 pandemic was associated with changes in Melanoma UK registry participants' QoL. Methods: QoL data, measured using EQ-5D and QLQ-C30 from 423 participants, were analysed. Data submitted between 03/2019 and 02/2020 were deemed pre-COVID-19 data; data submitted between 03/2020 and 03/2021 were considered as peri-pandemic data. A monthly average score was calculated for each domain of EQ-5D and QLQ-C30. T-tests were conducted to compare the individual domain scores calculated for the pre-and peri-pandemic periods. Results: EQ-5D: Mobility (p=0.03), self-care (p=0.03), usual activities (p=0.003), pain symptoms (p=0.03), and health in general (p=0.0004) improved during the pandemic. QLQ-C30: There was an observed improvement in physical (p=0.02), role (p=0.01), and social functioning (p=0.003). Fatigue (p=0.002) and pain symptoms (p=0.05) decreased during the pandemic. Participants also reported experiencing less financial difficulty (p=0.02) in comparison with the pre-pandemic period. No change in emotional well-being was observed. Conclusions: The QoL of patients with melanoma improved during the COVID-19 pandemic. Future research should involve qualitative interviews with melanoma patients and their caregivers to explore the mechanisms of this change, the role of support networks, and the impact on caregivers.

Chen J, 1 Gong CL, 2 Jiao X, 1 Zawadzki NK, 1 Persson U, 3 Hay JW, 1 Gu NY 4 1 University of Southern California, Los Angeles, CA, USA, 2 Children's Hospital Los Angeles, Los Angeles, CA, USA, 3 The Swedish Institute for Health Economics (IHE), Lund, Sweden, 4 NYG Technologies, Santa Clarita, CA, USA Objectives: To assess and compare the impact of the COVID-19 pandemic on healthrelated quality-of-life (HRQoL) in the United States, Sweden and Norway. Methods: Two waves of web-based survey were conducted in April 2020 and January 2021 to collect demographic data, COVID-19 status, behavior and employment changes related to COVID-19 in each country (EuroQol Grant: 246-2020RA). EQ-5D-5L was used to assess health status of respondents. Results were compared between the two waves to measure changes in HRQoL. One-way ANOVA was used to detect significant differences between countries, and t-tests for differences between waves. Results: We collected 2,734, 1,003 and 1,020 responses in Wave 1, and 2,252, 1,013 and 1,011 responses in Wave 2 for the US, Sweden, and Norway respectively. Corresponding mean (SD) EQ-VAS scores were 74.6 (619.2), 68.7 (621.4), and 69.2 (620.8) in Wave 1 (p,0.001), and 76.4 (618.6), 68.2 (620.3), and 67.8 (621.7) in Wave 2 (p,0.001). Between waves, only the VAS scores in the US were significantly different (p,0.001). Mean (SD) utility scores were 0.822 (60.222), 0.768 (60.260), and 0.808 (60.248) in wave 1 (p,0.001), and 0.823 (60.221), 0.783 (60.237), and 0.777 (60.271) in wave 2 (p,0.001); there were no significant differences between waves for all three countries. Anxiety/depression was consistently the most problematic EQ-5D-5L subdomain among Swedish and Americans (.50%), followed by pain/discomfort. .45% Norwegians also reported problems in anxiety/depression subdomain in both waves. The proportions reporting problems in anxiety/depression increased in wave 2 for Sweden and Norway, but decreased for the US. Conclusions: Population HRQoL in Sweden and Norway has been similar throughout the pandemic, while a rebound in population mean VAS was observed in the US. However, the large proportions reporting problems in anxiety/depression across waves in all 3 countries indicates that mental health issues resulting from the pandemic are a major concern. 

It was hypothesized that COVID-19 lockdown measures led to later admission of myocardial infarction (MI) patients to hospitals and, consequently, higher average case severity and mortality. The aim of this study was to compare MIassociated mortality between COVID-19 lockdown and pre-COVID-19 periods. Methods: We used German claims data from continuously insured adults hospitalized with a MI (ICD-10 I21), and compared 30-days mortality for cases in

Conclusions: Even if we cannot rule out the possibility of a higher MI-related mortality during COVID lockdown periods in nonhospitalized MI patients, we cannot confirm the hypothesis that hospitalized patients generally showed a higher mortality due to later admission to hospitals and thus more higher case severity at time of hospital admission